The draft National List includes drugs, the price of which is regulated by separate regulations.These include amlodipine, bisoprolol, enalapril, as well as insulins included in the Pilot Projects for the Treatment of Persons with Hypertension and Diabetes.At the same time, the draft National List does not include lisinopril, metoprolol, nifedipine, nebivolol, as well as drugs with a combination of active ingredients amlodipine with lisinopril, lisinopril with hydrochlorothiazide and enalapril with hydrochlorothiazide, which are subject to the Pilot Project on Drug Price Regulation for the treatment of persons with hypertension.The WHO Model List also does not include these drugs.In this case, it would be logical to exclude drugs from the draft National List, the prices for which are regulated by separate regulatory documents.